Cancer: Drugs

Health written question – answered on 8th September 2014.

Alert me about debates like this

Photo of Bob Neill Bob Neill Parliamentary Assembly of the Council of Europe (Substitute Member), Vice-Chair, Conservative Party

To ask the Secretary of State for Health

(1) with reference to the statement by Peter Clark of NHS England that cancer drugs on the list of treatments which are approved for funding must be re-evaluated, reported in The Guardian's article of 28 August 2014 entitled 'Cancer Drugs Fund gets £160 million more for innovative treatments' through what process cancer drugs will be re-evaluated; and whether cancer drugs will be subject to assessments of their cost-effectiveness;

(2) what cost-per-quality-adjusted life-year thresholds NHS England will attach to its assessments of the cost-effectiveness of cancer drugs for the purposes of assessing whether they should be funded through the Cancer Drugs Fund; and if he will make a statement.

Photo of George Freeman George Freeman The Parliamentary Under-Secretary of State for Business, Innovation and Skills, The Parliamentary Under-Secretary of State for Health

NHS England has oversight of the Cancer Drugs Fund.

NHS England has advised that work is currently underway to determine the process for reviewing drugs on its national list of cohort policies and on how best to assess costs in relation to clinical benefit delivered.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.